

Date: 02-11-2015

To,  
The Secretary,  
The B.S.E Limited  
Floor 25, P.J. Towers,  
Dalal Street,  
Mumbai. - 400 001

The Manager (Listing  
Department)  
The Ahmedabad Stock  
Exchange Ltd.,  
Kamadhenu Complex,  
Opp. Sahajanand College,  
Panjarapole,  
Ahmedabad

To,  
The Manager (Listing  
Department)  
The Madras Stock  
exchange,  
Chennai

Sub : Outcome of the Board meeting.

The meeting of the Board of Directors of the company was held at 04:30 pm today. The out come of the meeting is under:

The Board has considered and approved the minutes of the previous board meeting.

The Board has considered and approved the Standalone and Consolidated Un-audited financials for the halfyear/ Quarter ended 30<sup>th</sup> September, 2015.


The company has taken note of SEBI orders received by the promoters of the company .

There being no other matter meeting of the board of directors concluded with the vote of thanks.

Thanking you

Yours truly,  
for TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED.

Arun Kumar Bhangadia  
Managing Director  
DIN: 00021024



Trimurthi Drugs & Pharmaceuticals Ltd.

4-4-231/1/2 ABC, Inder Bagh, Sultan Bazar,

Hyderabad - 500 095, A.P., India

T: 040 2475 7370


W: [www.trimurthigroup.com](http://www.trimurthigroup.com)

CIN No: L67120TG1994PLC018956

**TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED**  
**STANDALONE UNAUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED SEPTEMBER, 2015**



Particulars	STATEMENT OF STANDALONE UNAUDITED RESULTS FOR QUARTER II AND THREE MONTHS ENDED 30-09-2015						(Rs. In Lakhs)
	3 Months ended 30-09-2015	Preceeding 3 months ended 30-06-2015	Corresponding 3 months ended 30-09-2014	Year to date figures for the current period ended 30-09-2015	Year to date figures for the previous year ended 30-09-2014	Year ended 31-03-2015	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
<b>1. Income From Operations</b>							
Net Sales / Income from Operations	0.00	0.00	(0.00)	0.00	31.40	31.40	
Other Operating Income	20.65	21.06	26.13	41.71	52.64	114.23	
<b>Total Operating Income(Net)</b>	<b>20.65</b>	<b>21.06</b>	<b>26.13</b>	<b>41.71</b>	<b>84.04</b>	<b>145.63</b>	
<b>2. Expenditure</b>							
a. Consumption of Raw Material	Nil	Nil	Nil	Nil	Nil	Nil	
b. Purchase of Traded Goods/Shares	0.00	0.00	0.00	0.00	0.08	0.08	
c. (Increase)/Decrease in stock in trade and work in Progress	0.00	0.00	0.00	0.00	32.21	32.21	
d. Employees Cost	5.67	4.14	0.97	9.81	2.44	6.22	
e. Rent	0.30	0.20	0.20	0.50	0.50	0.50	
f. Depreciation	6.12	8.45	7.67	14.57	15.33	39.57	
g. Other Expenditure	4.38	5.96	3.26	10.35	9.33	37.74	
<b>Total</b>	<b>16.47</b>	<b>18.75</b>	<b>12.09</b>	<b>35.22</b>	<b>59.89</b>	<b>115.83</b>	
<b>Profit/ (Loss) from Operations before Other Income, Finance Cost &amp; Exceptional Items (2-3. 1)</b>	<b>4.18</b>	<b>2.32</b>	<b>14.04</b>	<b>6.50</b>	<b>24.15</b>	<b>29.80</b>	
<b>4. Other Income</b>	<b>3.79</b>	<b>4.56</b>	<b>0.00</b>	<b>8.36</b>	<b>0.00</b>	<b>(20.63)</b>	
<b>Profit/ (Loss) from Ordinary Acitvites before Finance Cost &amp; Exceptional Items (3+4)</b>	<b>7.97</b>	<b>6.88</b>	<b>14.04</b>	<b>14.85</b>	<b>24.15</b>	<b>9.17</b>	
6. Finance Cost	0.00	0.00	0.15	0.00	0.15	0.39	
<b>7. Profit/ (Loss) from Ordinary activities after finance cost but before exceptional items (5+6)</b>	<b>7.97</b>	<b>6.88</b>	<b>13.89</b>	<b>14.85</b>	<b>24.00</b>	<b>8.78</b>	
8. Exceptional Items	Nil	Nil	Nil	Nil	Nil	Nil	
<b>9. Profit/ (Loss) from Ordinary activities before tax (7+8)</b>	<b>7.97</b>	<b>6.88</b>	<b>13.89</b>	<b>14.85</b>	<b>24.00</b>	<b>8.78</b>	
10. Tax Expense (Including Deferred Tax)	2.12	1.67	4.29	3.79	7.79	6.92	
<b>11. Net Profit/ (Loss) from Ordinary activities after Tax (9+10)</b>	<b>5.86</b>	<b>5.21</b>	<b>9.60</b>	<b>11.06</b>	<b>16.20</b>	<b>1.86</b>	
12. Extraorindary Items(Net Of Tax Expenses)	Nil	Nil	Nil	Nil	Nil	Nil	
<b>13. Net Profit/ (Loss) for the period (11+12)</b>	<b>5.86</b>	<b>5.21</b>	<b>9.60</b>	<b>11.06</b>	<b>16.20</b>	<b>1.86</b>	
14. Share Of Profit/(loss) Of Associates	-NA-	-NA-	-NA-	-NA-	-NA-	-NA-	
15. Minority Interest	-NA-	-NA-	-NA-	-NA-	-NA-	-NA-	
<b>Net Profit/ (Loss) after taxes, Minority Interest and Share Of Profit/(Loss) of Associates (13+14+15)</b>	<b>5.86</b>	<b>5.21</b>	<b>9.60</b>	<b>11.06</b>	<b>16.20</b>	<b>1.86</b>	
16. Paid-up Equity Share Capital (Face Value of Rs.10/- each)	810.00	810.00	810.00	810.00	810.00	810.00	
17. Reserves excluding revaluation reserves, as per balance sheet of previous accounting year	324.27	324.27	334.84	324.27	334.84	334.84	
<b>19. Earnings Per Share (EPS)</b>							
i. Basic & Diluted before extraordinary items (not annualised)	0.07	0.06	0.12	0.14	0.20	0.02	
ii. Basic & Diluted after extraordinary items (not annualised)	0.07	0.06	0.12	0.14	0.20	0.02	



**Trimurthi Drugs & Pharmaceuticals Ltd.**

4-4-231/1/2 ABC, Inder Bagh, Sultan Bazar,  
 Hyderabad - 500 095, A.P., India

T: 040 2475 7370

W: [www.trimurthigroup.com](http://www.trimurthigroup.com)

CIN No: L67120TG1994PLC018956

**TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED**  
**STANDALONE UNAUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED SEPTEMBER, 2015**



**PART-II**

**SELECT INFORMATION FOR QUARTER II AND THREE MONTHS ENDED 30-09-2015**

Particulars	3 Months ended 30-09-2015	Preceeding 3 months ended 31-06-2015	Corresponding 3 months ended 30-09-2014	Year to date figures for the current period ended 30-09-2015	Year to date figures for the previous period ended 30-09-2014	Year ended 31-03-2015
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>A. Particulars Of Share Holding</b>						
1. Public Share Holding						
- Number of Shares	2849600	2849600	3366200	2849600	3366200	2849600
- Percentage of shareholding	35.18%	35.18%	41.56%	35.18%	41.56%	35.18%
2. Promoters and promoter group shareholding						
a. Pledged / encumbered						
- No of Equity Shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
b. Non encumbered						
- No of Equity Shares	5250400	5250400	4733800	5250400	4733800	5250400
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	64.82%	64.82%	58.44%	64.82%	58.44%	64.82%
<b>Particulars</b>						
<b>3 Months Ended ( 30/09/2015)</b>						
<b>B. Investor Complaints</b>						
Pending at the beginning of the quarter				-NIL-		
Received during the quarter				-NIL-		
Disposed during the quarter				-NIL-		
Remaining unsolved during the quarter				-NIL-		

**Segment Reporting**

Particulars	Quarters ended			Period ended		Year ended
	30/09/2015	31/06/2015	30/09/2014	30/09/2015	30/09/2014	31/03/2015
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1. Segment Revenue</b>						
a. Pharma Business	0.00	0.00	0.00	0.00	31.40	31.40
b. Financial Services	20.65	21.06	26.13	41.71	52.64	114.23
c. Investments	3.79	4.56	0.00	8.36	0.00	(19.67)
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00	0.00
<b>Total</b>	<b>24.44</b>	<b>25.63</b>	<b>26.13</b>	<b>50.07</b>	<b>84.04</b>	<b>125.96</b>
<b>Less: Inter Segment Revenue</b>	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>Net Sales/ Income From Operations</b>	<b>24.44</b>	<b>25.63</b>	<b>26.13</b>	<b>50.07</b>	<b>84.04</b>	<b>125.96</b>
<b>2. Segment Profits ( Before tax &amp; Interest From Each Segment)</b>						
a. Pharma Business	0.00	0.00	0.00	0.00	(1.47)	(1.47)
b. Financial Services	4.85	2.72	13.89	7.57	25.47	30.81
c. Investments	3.12	4.16	0.00	7.28	0.00	(20.56)
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00	0.00
<b>Total</b>	<b>7.97</b>	<b>6.88</b>	<b>13.89</b>	<b>14.85</b>	<b>24.00</b>	<b>8.78</b>
<b>Less:</b>						
i. Interest	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
ii. Other Un-allocable expenses net off	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
iii. Un-allocable Income	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>Total Profit Before Tax</b>	<b>7.97</b>	<b>6.88</b>	<b>13.89</b>	<b>14.85</b>	<b>24.00</b>	<b>8.78</b>
<b>3. Capital Employed</b>						
a. Pharma Business	13.82	10.34	18.98	13.82	18.98	11.83
b. Financial Services	914.13	862.25	1080.57	914.13	1080.57	962.16
c. Investments	207.38	251.89	31.50	207.38	31.50	140.28
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00	0.00
<b>Total</b>	<b>1135.33</b>	<b>1124.48</b>	<b>1131.05</b>	<b>1135.33</b>	<b>1131.05</b>	<b>1114.27</b>

**Notes:**

1. The above results have been taken on record by the board of directors of the company at their meeting held on 02-11-2015.
2. The financial results for the quarter ended 30-09-2015 have been reviewed by the statutory auditors in pursuance of listing agreement.
3. In segment reporting common assets that are used interchangeable not allocated to the individual segment above.

Place : Hyderabad,  
Date : 02-11-2015.

**Trimurthi Drugs & Pharmaceuticals Ltd.**

4-4-231/1/2 ABC, Inder Bagh, Sultan Bazar,

Hyderabad - 500 095, A.P., India

T: 040 2475 7370

W: [www.trimurthigroup.com](http://www.trimurthigroup.com)

**CIN No: L67120TG1994PLC018956**



**TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED**  
**STANDALONE ASSETS AND LIABILITIES FOR THE HALF YEAR ENDED ON 30-09-2015**



Particulars	As at 30/09/2015	As at 31/03/2015
<b>A. EQUITY AND LIABILITIES</b>		
<b>1. Share Holders' Funds:</b>		
(a) Share Capital	810.00	810.00
(b) Reserves and Surplus	335.33	324.27
(c) Money received against warrants	0.00	0.00
<b>Sub-Total Share Holders' Funds</b>	<b>1145.33</b>	<b>1134.27</b>
<b>2. Share Application pending for Allotment</b>	-Nil-	-Nil-
<b>3. Minority Interest*</b>	-Nil-	-Nil-
<b>4. Non Current Liabilities:</b>		
(a) Long Term Borrowings	-Nil-	-Nil-
(b) Deferred Tax Liabilities (Net)	5.33	8.27
(c) Other Long Term Liabilities	-Nil-	-Nil-
(d) Long Term Provisions	-Nil-	-Nil-
<b>Sub-Total Non Current Liabilities</b>	<b>5.33</b>	<b>8.27</b>
<b>4. Current Liabilities</b>		
(a) Short Term Borrowings	-Nil-	-Nil-
(b) Trade Payables	-Nil-	-Nil-
(c) Other Current Liabilities	6.60	7.48
(d) Short Term Provisions	6.73	10.24
(e) Inter Division	-Nil-	-Nil-
<b>Sub-Total Current Liabilities</b>	<b>13.33</b>	<b>17.72</b>
<b>TOTAL EQUITY &amp; LIABILITIES</b>	<b>1163.99</b>	<b>1160.26</b>
<b>B. ASSETS</b>		
<b>1. Non-Current Assets:</b>		
(a) Fixed Assets	60.87	74.94
(b) Non-Current Investments	207.38	140.28
(c) Deferred Tax Assets (Net)	-Nil-	-Nil-
(d) Long Term Loans and Advances	20.51	20.52
(e) Other Non-Current Assets	-Nil-	-Nil-
<b>Sub-Total Non Current Assets</b>	<b>288.76</b>	<b>235.74</b>
<b>2. Current Assets:</b>		
(a) Current Investments	-Nil-	-Nil-
(b) Inventories	-Nil-	-Nil-
(c) Trade Receivables	13.82	11.83
(d) Cash & Cash Equivalents	15.16	17.48
(e) Short Term Loans and Advances	842.07	881.46
(f) Other Current Assets	4.18	13.75
<b>Sub-Total Current Assets</b>	<b>875.23</b>	<b>924.52</b>
<b>TOTAL ASSETS</b>	<b>1163.99</b>	<b>1160.26</b>

Trimurthi Drugs & Pharmaceuticals Ltd.


4-4-231/1/2 ABC, Inder Bagh, Sultan Bazar,

Hyderabad - 500 095, A.P., India

T: 040 2475 7370

W: [www.trimurthigroup.com](http://www.trimurthigroup.com)

CIN No: L67120TG1994PLC018956



**TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED**  
 CONSOLIDATED UNAUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED SEPTEMBER, 2015  
 CONSOLIDATED UNAUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED SEPTEMBER, 2015




**TRIMURTHI**  
Group

(Rs. In Lakhs)

**PART-I**

**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR QUARTER II AND THREE MONTHS ENDED 30/09/2015**

Particulars	3 Months ended 30-09-2015	Preceeding 3 months ended 30-06-2015	Corresponding 3 months ended 30-09-2014	Year to date figures for the current period ended 30-09-2015	Year to date figures for the previous period ended 30-09-2014	Year ended 31-03-2015
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1. Income From Operations</b>						
Net Sales / Income from Operations	120.73	125.14	131.64	245.87	277.35	511.51
Other Operating Income	22.64	23.76	29.00	46.40	57.87	123.45
<b>Total Operating Income(Net)</b>	<b>143.37</b>	<b>148.90</b>	<b>160.64</b>	<b>292.27</b>	<b>335.22</b>	<b>634.96</b>
<b>2. Expenditure</b>						
a. Consumption of Raw Material	Nil	Nil	Nil	Nil	Nil	Nil
b. Purchase of Traded Goods	115.36	109.30	113.65	224.67	245.36	472.24
c. (Increase)/Decrease in stock in trade and work in Progress	(10.03)	0.86	0.27	(9.17)	3.28	(12.80)
d. Employees Cost	12.71	11.46	5.63	24.17	10.39	35.86
e. Depreciation	6.98	8.81	7.70	15.79	15.37	40.89
f. Other Expenditure	9.74	9.65	6.20	19.39	15.33	50.63
<b>Total</b>	<b>134.77</b>	<b>140.08</b>	<b>133.45</b>	<b>274.85</b>	<b>289.73</b>	<b>586.82</b>
<b>Profit/ (Loss) from Operations before Other</b>						
<b>3. Income, Finance Cost &amp; Exceptional Items (2-1)</b>	<b>8.60</b>	<b>8.83</b>	<b>27.19</b>	<b>17.43</b>	<b>45.49</b>	<b>48.14</b>
<b>4. Other Income</b>	3.90	4.56	0.00	8.46	0.00	(20.63)
<b>Profit/ (Loss) from Ordinary Acitvites before</b>						
<b>5. Finance Cost &amp; Exceptional Items (3±4)</b>	<b>12.50</b>	<b>13.39</b>	<b>27.19</b>	<b>25.89</b>	<b>45.49</b>	<b>27.51</b>
<b>6. Finance Cost</b>	0.00	0.00	0.15	0.00	0.15	0.39
<b>7. Profit/ (Loss) from Ordinary activities after finance cost but before exceptional items (5±6)</b>	<b>12.50</b>	<b>13.39</b>	<b>27.04</b>	<b>25.89</b>	<b>45.34</b>	<b>27.12</b>
<b>8. Exceptional Items</b>	Nil	Nil	Nil	Nil	Nil	Nil
<b>9. Profit/ (Loss) from Ordinary activities before tax (7±8)</b>	<b>12.50</b>	<b>13.39</b>	<b>27.04</b>	<b>25.89</b>	<b>45.34</b>	<b>27.12</b>
<b>10. Tax Expense (Including Deferred Tax)</b>	4.31	3.61	8.38	7.92	14.40	12.94
<b>11. Net Profit/ (Loss) from Ordinary activities after Tax (9±10)</b>	<b>8.20</b>	<b>9.78</b>	<b>18.66</b>	<b>17.97</b>	<b>30.94</b>	<b>14.18</b>
<b>12. Extraordianry Items(Net Of Tax Expenses)</b>	Nil	Nil	Nil	Nil	Nil	Nil
<b>13. Net Profit/ (Loss) for the period (11±12)</b>	<b>8.20</b>	<b>9.78</b>	<b>18.66</b>	<b>17.97</b>	<b>30.94</b>	<b>14.18</b>
<b>14. Share Of Profit/(loss) Of Associates</b>	-NA-	-NA-	-NA-	-NA-	-NA-	-NA-
<b>15. Minority Interest</b>	<b>1.66</b>	<b>1.78</b>	<b>-NA-</b>	<b>3.44</b>	<b>-NA-</b>	<b>5.67</b>
<b>Net Profit/ (Loss) after taxes, Minority Interest and Share Of Profit/(Loss) of Associates (13±14±15)</b>	<b>6.54</b>	<b>8.00</b>	<b>18.66</b>	<b>14.53</b>	<b>30.94</b>	<b>8.51</b>
<b>16. Paid-up Equity Share Capital (Face Value of Rs.10/- each)</b>	810.00	810.00	810.00	810.00	810.00	810.00
<b>17. Reserves excluding revaluation reserves as per balance sheet of previous accounting year</b>	332.90	332.90	334.84	332.90	334.84	336.82
<b>19. Earnings Per Share (EPS)</b>						
<b>i. Basic &amp; Diluted before extraordinary items (not annualised)</b>	<b>0.08</b>	<b>0.10</b>	<b>0.23</b>	<b>0.18</b>	<b>0.38</b>	<b>0.11</b>
<b>ii. Basic &amp; Diluted after extraordinary items (not annualised)</b>	<b>0.08</b>	<b>0.10</b>	<b>0.23</b>	<b>0.18</b>	<b>0.38</b>	<b>0.11</b>



**Trimurthi Drugs & Pharmaceuticals Ltd.**

4-4-231/1/2 ABC, Inder Bagh, Sultan Bazar,

Hyderabad - 500 095, A.P., India

T: 040 2475 7370

W: www.trimurthigroup.com

**CIN No: L67120TG1994PLC018956**

# TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED

CONSOLIDATED UNAUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED SEPTEMBER, 2015



## PART-II

### Select Information for Quarter II and Three months Ended 30/09/2015

Particulars	3 Months ended 30-09-2015	Preceeding 3 months ended 30-06-2015	Corresponding 3 months ended 30-09-2014	Year to date figures for the current period ended 30-09-2015	Year to date figures for the current period ended 30-09-2014	Year ended 31-03-2015
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>A. Particulars Of Share Holding</b>						
1. Public Share Holding						
- Number of Shares	2849600	2849600	3102200	2849600	3102200	2849600
- Percentage of shareholding	35.18%	35.18%	38.30%	35.18%	38.30%	35.18%
2. Promoters and promoter group shareholding						
a. Pledged / encumbered						
- No of Equity Shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
b. Non encumbered						
- No of Equity Shares	5250400	5250400	4997800	5250400	4997800	5250400
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	64.82%	64.82%	61.70%	64.82%	61.70%	64.82%
<b>Particulars</b>				<b>6 Months Ended ( 30/09/2015)</b>		
<b>B. Investor Complaints</b>						
Pending at the beginning of the quarter					-NIL-	
Received during the quarter					-NIL-	
Disposed during the quarter					-NIL-	
Remaining unsolved during the quarter					-NIL-	

### Segment Reporting

Particulars	Quarters ended			Period ended		Year ended
	30/09/2015	30/06/2015	30/09/2014	30/09/2015	30/09/2014	31/03/2015
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1. Segment Revenue</b>						
a. Pharma Business	122.68	127.32	163.43	250.00	311.45	520.68
b. Financial Services	20.69	21.58	26.13	42.28	52.64	114.28
c. Investments	3.90	4.56	(0.05)	8.46	0.00	(19.67)
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00	0.00
<b>Total</b>	<b>147.27</b>	<b>153.47</b>	<b>189.51</b>	<b>300.74</b>	<b>364.09</b>	<b>615.29</b>
<b>Less: Inter Segment Revenue</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>
<b>Net Sales/ Income From Operations</b>	<b>147.27</b>	<b>153.47</b>	<b>189.51</b>	<b>300.74</b>	<b>364.09</b>	<b>615.29</b>
<b>2. Segment Profits ( Before tax &amp; Interest From Each Segment)</b>						
a. Pharma Business	7.34	5.98	13.14	13.32	19.87	16.82
b. Financial Services	1.93	3.24	13.89	5.18	25.47	31.00
c. Investments	3.22	4.17	0.00	7.39	0.00	(20.70)
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00	0.00
<b>Total</b>	<b>12.50</b>	<b>13.39</b>	<b>27.03</b>	<b>25.89</b>	<b>45.34</b>	<b>27.12</b>
<b>Less:</b>						
i. Interest	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
ii. Other Un-allocable expenses net off	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
iii. Un-allocable Income	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>Total Profit Before Tax</b>	<b>12.50</b>	<b>13.39</b>	<b>27.03</b>	<b>25.89</b>	<b>45.34</b>	<b>27.12</b>
<b>3. Capital Employed</b>						
a. Pharma Business	85.66	77.36	75.39	85.66	75.39	68.68
b. Financial Services	1039.60	990.21	1032.21	1039.60	1032.21	940.43
c. Investments	75.58	120.09	31.50	75.58	31.50	113.79
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00	0.00
<b>Total</b>	<b>1200.85</b>	<b>1187.65</b>	<b>1139.10</b>	<b>1200.85</b>	<b>1139.10</b>	<b>1122.90</b>

### Notes:

1. The above results have been taken on record by the board of directors of the company at their meeting held on **02-11-2015**.
2. The financial results for the quarter ended 30-09-2015 have been reviewed by the statutory auditors in pursuance of listing agreement.
3. In segment reporting common assets that are used interchangeable not allocated to the individual segment above.

Place : Hyderabad,  
Date : 02-11-2015.

**Trimurthi Drugs & Pharmaceuticals Ltd.**

4-4-231/1/2 ABC, Inder Bagh, Sultan Bazar,

Hyderabad - 500 095, A.P., India

T: 040 2475 7370

W: [www.trimurthigroup.com](http://www.trimurthigroup.com)

CIN No: L67120TG1994PLC018956





**TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED**  
CONSOLIDATED ASSETS AND LIABILITIES FOR THE HALF YEAR ENDED ON 30-09-2015

(Rupees in Lacs)

Particulars	As at 30/09/2015	As at 31/03/2015
<b>A. EQUITY AND LIABILITIES</b>		
<b>1. Share Holders' Funds:</b>		
(a) Share Capital	810.00	810.00
(b) Reserves and Surplus	349.73	332.90
(c) Money received against warrants		
<b>Sub-Total Share Holders' Funds</b>	<b>1159.73</b>	<b>1142.90</b>
<b>2. Share Application pending for Allotment</b>	-Nil-	-Nil-
<b>3. Minority Interest*</b>	51.11	27.54
<b>4. Non Current Liabilities:</b>		
(a) Long Term Borrowings	-Nil-	-Nil-
(b) Deferred Tax Liabilities (Net)	5.37	8.32
(c) Other Long Term Liabilities	-Nil-	-Nil-
(d) Long Term Provisions	-Nil-	-Nil-
<b>Sub-Total Non Current Liabilities</b>	<b>5.37</b>	<b>8.32</b>
<b>5. Current Liabilities</b>		
(a) Short Term Borrowings	-Nil-	-Nil-
(b) Trade Payables	68.32	48.07
(c) Other Current Liabilities	10.43	8.48
(d) Short Term Provisions	10.86	16.22
(e) Inter Division	-Nil-	-Nil-
<b>Sub-Total Current Liabilities</b>	<b>89.61</b>	<b>72.77</b>
<b>TOTAL EQUITY &amp; LIABILITIES</b>	<b>1305.82</b>	<b>1251.53</b>
<b>B. ASSETS</b>		
<b>1. Non-Current Assets:</b>		
(a) Fixed Assets	75.23	75.28
(b) Non-Current Investments	75.58	113.78
(c) Deferred Tax Assets (Net)	-Nil-	-Nil-
(d) Long Term Loans and Advances	20.51	20.51
(e) Other Non-Current Assets	-Nil-	-Nil-
<b>Sub-Total Non Current Assets</b>	<b>171.32</b>	<b>209.57</b>
<b>2. Current Assets:</b>		
(a) Current Investments	-Nil-	-Nil-
(b) Inventories	54.18	45.01
(c) Trade Receivables	81.89	71.75
(d) Cash & Cash Equivalents	134.22	21.80
(e) Short Term Loans and Advances	843.16	881.24
(f) Other Current Assets	21.05	22.16
<b>Sub-Total Current Assets</b>	<b>1134.50</b>	<b>1041.96</b>
<b>TOTAL ASSETS</b>	<b>1305.82</b>	<b>1251.53</b>

Trimurthi Drugs & Pharmaceuticals Ltd.

4-4-231/1/2 ABC, Inder Bagh, Sultan Bazar,  
Hyderabad - 500 095, A.P., India

T: 040 2475 7370

W: [www.trimurthigroup.com](http://www.trimurthigroup.com)

CIN No: L67120TG1994PLC018956





# K. Venkateswara Rao & Associates

Chartered Accountants

Door No. 3-5-907/2, Flat No.402, Mahavir Lok, Himayathnagar Main Road, Hyderabad - 500 029.  
e-mail: v\_kommineni@yahoo.com

## Annexure V to Clause 41

Review Report to:


The Board of Directors,  
Trimurthi Drugs & Pharmaceuticals Limited.

We have reviewed the accompanying statement of unaudited financial results of M/s **TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED** for the period ended **30<sup>th</sup> September, 2015**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement(SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and this provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards (Note 1) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that is contains any material misstatement.

K. VENKATESWARA RAO & ASSOCIATES  
CHARTERED ACCOUNTANTS  
FRN : 006374S



PLACE : HYDERABAD  
DATE : 02.11.2015